Veracyte and Vericel each hold earnings calls to review their Q2 2026 performance and business updates, according to materials and call coverage from Seeking Alpha and Yahoo Finance. Veracyte’s Q2 2026 discussion is presented through both a transcript and an earnings call presentation, covering company performance, operational progress, and outlook. Vericel’s Q2 2026 reporting likewise includes an earnings call transcript and a presentation, and Yahoo Finance highlights key points from Vericel’s earnings call. Across the sources, the common theme is that both companies discuss results for the quarter and provide commentary on their respective programs and commercial activities. The reports are presented as corporate earnings communications rather than independent investigations, and the available excerpts focus on the fact that each company shares its quarterly performance, management’s perspective, and forward-looking guidance during its call. However, without the specific figures and statements included in the provided source text, a detailed comparison of revenue, profitability, cash flow, or specific clinical/commercial milestones cannot be confirmed from the supplied summaries.